
ELVN Stock Forecast & Price Target
ELVN Analyst Ratings
Bulls say
Enliven Therapeutics Inc. is implementing cost-saving measures, including a workforce reduction, which reflects prudent financial management in a challenging biotechnology sector. The company is strategically focusing on the development of its HER3-targeting ADC, EO-1022, which may result in significant future revenue opportunities starting in 2031. Additionally, the adjustments made to the financial model, including a focus on early-stage products and expense management, suggest that the company is positioning itself for a more stable financial trajectory.
Bears say
Enliven Therapeutics has recently decided to discontinue the development of its Claudin 18.2-targeting ADC, EO-3021, due to its lower-than-expected efficacy in a Phase 1 study, which raises concerns about the viability of this product candidate. This decision indicates a potential setback in Enliven's pipeline, as the comparatively low efficacy may deter further investment despite the drug being well tolerated. Additionally, the revision of the 12-month price target down to $1.00 from $6.00 suggests a significant decline in confidence regarding the company's future financial performance and product development prospects.
This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ELVN Analyst Forecast & Price Prediction
Start investing in ELVN
Order type
Buy in
Order amount
Est. shares
0 shares